Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, Searls D, Selim M
Department of Neurology, Stroke Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Palmer 127, Boston, MA 02215, USA.
Neurology. 2008 Oct 28;71(18):1417-23. doi: 10.1212/01.wnl.0000330297.58334.dd.
To develop a grading scale to predict the risk of intracerebral hemorrhage (ICH) and prognosis after treatment with IV tissue-plasminogen activator (t-PA) in patients with ischemic stroke.
We constructed a five-point scale based on NIH Stroke Scale score, extent of hypodensity on CT scan, serum glucose at baseline, and history of diabetes to predict the risk of hemorrhage after thrombolysis (HAT score). We evaluated the predictive ability of this scale, using c-statistics, in two independent cohorts: the t-PA treated group in the National Institute of Neurological Disorders and Stroke study, and consecutive patients treated with IV t-PA at our institution.
The percentage of patients who developed any ICH after t-PA increased with higher scores in both cohorts. Collectively, the rate of any symptomatic ICH was 2% (0 point), 5% (1 point), 10% (2 points), 15% (3 points), and 44% (>3 points). The c-statistic was 0.72 (95% CI 0.65-0.79; p < 0.001) for all hemorrhages; 0.74 (0.63-0.84; p < 0.001) for symptomatic hemorrhages; and 0.79 (0.70-0.88; p < 0.001) for hemorrhages with final fatal outcome. Similar results were obtained when each cohort was analyzed separately. The score also reasonably predicted good (mRS < or = 2) (c-statistic 0.75; 0.69-0.80; p < 0.001) and catastrophic (mRS > or = 5) (0.78; 0.72-0.84; p < 0.001) functional outcomes on day 90 in the National Institute of Neurological Disorders and Stroke t-PA-treated patients.
The hemorrhage after thrombolysis (HAT) score is a practical, quick, and easy-to-perform scale that allows reasonable risk stratification of intracerebral hemorrhage after IV tissue-plasminogen activator (t-PA). However, the prognostic value of this scale and its use to predict the net benefit from t-PA needs to be refined and prospectively confirmed in a larger cohort of patients before it can be used in clinical decision-making.
制定一种分级量表,以预测缺血性卒中患者静脉注射组织型纤溶酶原激活剂(t-PA)治疗后的脑出血(ICH)风险及预后。
我们基于美国国立卫生研究院卒中量表评分、CT扫描低密度范围、基线血清葡萄糖及糖尿病史构建了一个五分制量表,以预测溶栓后出血风险(HAT评分)。我们在两个独立队列中使用c统计量评估了该量表的预测能力:国立神经疾病与卒中研究所研究中的t-PA治疗组,以及我们机构接受静脉t-PA治疗的连续患者。
在两个队列中,t-PA治疗后发生任何脑出血的患者百分比均随评分升高而增加。总体而言,任何有症状脑出血的发生率分别为2%(0分)、5%(1分)、10%(2分)、15%(3分)和44%(>3分)。所有脑出血的c统计量为0.72(95%CI 0.65 - 0.79;p < 0.001);有症状脑出血的c统计量为0.74(0.63 - 0.84;p < 0.001);最终导致死亡的脑出血的c统计量为0.79(0.70 - 0.88;p < 0.001)。对每个队列分别进行分析时也得到了类似结果。该评分还合理地预测了国立神经疾病与卒中研究所t-PA治疗患者在第90天时良好(改良Rankin量表评分≤2)(c统计量0.75;0.69 - 0.80;p < 0.001)和灾难性(改良Rankin量表评分≥5)(0.78;0.72 - 0.84;p < 0.001)的功能结局。
溶栓后出血(HAT)评分是一种实用、快速且易于实施的量表,可对静脉注射组织型纤溶酶原激活剂(t-PA)后的脑出血进行合理的风险分层。然而,在可用于临床决策之前,该量表的预后价值及其用于预测t-PA净获益的情况需要在更大规模的患者队列中进一步完善并前瞻性地加以证实。